Epidermal Growth Factor Receptor ( EGFR ) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma

Autor: Michela Visani, Dario de Biase, Giovanna Cavallo, Giovanni Tallini, Giorgia Acquaviva, Alba A. Brandes, Giovenzio Genestreti, Roberta Degli Esposti, Monica Di Battista, Thomas Brand, Annalisa Pession
Přispěvatelé: Genestreti, Giovenzio, de Biase, Dario, Di Battista, Monica, Cavallo, Giovanna, Degli Esposti, Roberta, Visani, Michela, Acquaviva, Giorgia, Brand, Thoma, Pession, Annalisa, Tallini, Giovanni, Brandes, Alba A.
Rok vydání: 2017
Předmět:
Zdroj: Clinical Lung Cancer. 18:e215-e217
ISSN: 1525-7304
Popis: Clinical Practice Points • p.E749Q is an uncommon EGFR mutation in exon 19 with unknown clinical significance. • A patient with lung adenocarcinoma harboring the p.E749Q EGFR mutation does not respond to gefitinib. • The p.E749Q mutation seems to be correlated with resistance to tyrosine kinase inhibitors. • Conventional chemotherapy should be the treatment of choice in patients with the p.E749Q mutation.
Databáze: OpenAIRE